Literature DB >> 15138710

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.

Catherine Dutreix1, Bin Peng, Guenther Mehring, Michael Hayes, Renaud Capdeville, Rolf Pokorny, Michael Seiberling.   

Abstract

The study under discussion was a drug-drug interaction study in which the effect of ketoconazole, a potent CYP450 3A4 inhibitor, on the pharmacokinetics of Glivec (imatinib) was investigated. A total of 14 healthy subjects (13 male, 1 female) were enrolled in this study. Each subject received a single oral dose of imatinib 200 mg alone, and a single oral dose of imatinib 200 mg coadministered with a single oral dose of ketoconazole 400 mg according to a two-period crossover design. The treatment sequence was randomly allocated. Subtherapeutic imatinib doses and a short exposure were tested in order not to overexpose the healthy volunteers. There was a minimum 7-day washout period between the two sequences. Blood samples for determination of plasma concentrations were taken up to 96 h after dosing. Imatinib and CGP74588 (main metabolite of imatinib) concentrations were measured using LC/MS/MS method and pharmacokinetic parameters were estimated by a non-compartmental analysis. Following ketoconazole coadministration, the mean imatinib C(max), AUC((0-24)) and AUC((0- infinity )) increased significantly by 26% ( P<0.005), 40% ( P<0.0005) and 40% ( P <0.0005), respectively. There was a statistically significant decrease in apparent clearance (CL/f) of imatinib with a mean reduction of 28.6% ( P<0.0005). The mean C(max) and AUC((0-24)) of the metabolite CGP74588 decreased significantly by 22.6% ( P<0.005) and 13% ( P<0.05) after ketoconazole treatment, although the AUC((0- infinity )) of CGP74588 only decreased by 5% ( P=0.28). Coadministration of ketoconazole and imatinib caused a 40% increase in exposure to imatinib in healthy volunteers. Given its previously demonstrated safety profile, this increased exposure to imatinib is likely to be clinically significant only at high doses. This interaction should be considered when administering inhibitors of the CYP3A family in combination with imatinib.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138710     DOI: 10.1007/s00280-004-0832-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  28 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.

Authors:  Bella Pajares; Esperanza Torres; José Manuel Trigo; María Isabel Sáez; Nuria Ribelles; Begoña Jiménez; Emilio Alba
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

3.  Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.

Authors:  Noelia Nebot; Severine Crettol; Fabrizio d'Esposito; Bruce Tattam; David E Hibbs; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

4.  Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

Authors:  A M Filppula; J Laitila; P J Neuvonen; J T Backman
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

5.  Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Authors:  Jan H Beumer; Venkateswaran C Pillai; Robert A Parise; Susan M Christner; Brian F Kiesel; Michelle A Rudek; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2015-09-19       Impact factor: 4.335

6.  CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.

Authors:  Henrik Gréen; Karin Skoglund; Franz Rommel; Rajaa A Mirghani; Kourosh Lotfi
Journal:  Eur J Clin Pharmacol       Date:  2010-04       Impact factor: 2.953

7.  Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.

Authors:  Yanfeng Wang; Li Zhou; Catherine Dutreix; Elisabeth Leroy; Qi Yin; Venkat Sethuraman; Gilles-Jacques Riviere; Ophelia Q P Yin; Horst Schran; Zhi-Xiang Shen
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

Review 8.  Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.

Authors:  John F Deeken; Liron Pantanowitz; Bruce J Dezube
Journal:  Curr Opin Oncol       Date:  2009-09       Impact factor: 3.645

9.  Reduced exposure of imatinib after coadministration with acetaminophen in mice.

Authors:  Inthisham Nassar; Thanikachalam Pasupati; John Paul Judson; Ignacio Segarra
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

10.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.